Saskatoon nurse recounts working in Gaza when Israel broke ceasefire
Saskatoon nurse Casey Eberl was serving in Nasser Hospital in southern Gaza. Israel has struck the hospital multiple times.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
7 hours ago
- Winnipeg Free Press
Arizona governor vetoes bill to ban teaching antisemitism in Arizona's public schools
PHOENIX (AP) — Arizona Gov. Katie Hobbs has vetoed a proposal that would ban teaching antisemitism at the state's public K-12 schools, universities and colleges and expose educators who violate the new rules to discipline and lawsuits. On Tuesday, the Democratic governor said the bill is not about antisemitism but rather about attacking teachers. 'It puts an unacceptable level of personal liability in place for our public school, community college, and university educators and staff, opening them up to threats of personally costly lawsuits,' she said in a statement. Additionally, it sets a dangerous precedent that unfairly targets public school teachers while shielding private school staff.' The measure cleared the Legislature on Wednesday on a 33-20 vote by the House, including a few Democrats who crossed party lines to support it. It's one of a few proposals to combat antisemitism across the country. The proposal would prohibit teachers and administrators from teaching or promoting antisemitism or antisemitic actions that create a hostile environment, calling for the genocide of any group or requiring students to advocate for an antisemitic point of view. It also would bar public schools from using public money to support the teaching of antisemitism. Educators would personally be responsible for covering the costs of damages in lawsuits for violating the rules. Democrats tried but failed to remove the lawsuit provision and swap out references to antisemitism within the bill with 'unlawful discrimination' to reflect other discrimination. The bill's chief sponsor, Republican Rep. Michael Way, of Queen Creek, has said his proposal would create accountability when educators fail to protect students from the rise in antisemitism since the start of the Israel-Hamas war. Opponents say the bill aims to silence people who want to speak out on the oppression of Palestinians and opens up educators to personal legal liability in lawsuits students could file. Students over the age of 18 and the parents of younger pupils would be able to file lawsuits over violations that create a hostile education environment, leaving teachers responsible for paying any damages that may be awarded, denying them immunity and prohibiting the state from paying any judgments arising from any such lawsuits. The proposal would create a process for punishing those who break the rules. At K-12 schools, a first-offense violation would lead to a reprimand, a suspension of a teacher or principal's certificate for a second offense and a revocation of the certificate for a third offense. At colleges and universities, violators would face a reprimand on first offense, a suspension without pay for a second offense and termination for a third offense. The proposal also would require colleges and universities to consider violations by employees to be a negative factor when making employment or tenure decisions. Under the proposal, universities and colleges couldn't recognize any student organization that invites a guest speaker who incites antisemitism, encourages its members to engage in antisemitism or calls for the genocide of any group. Elsewhere in the U.S., a Louisiana lawmaker is pushing a resolution that asks universities to adopt policies to combat antisemitism on campuses and collect data on antisemitism-related reports and complaints. And a Michigan lawmaker has proposed putting a definition of antisemitism into the state's civil rights law.
Globe and Mail
8 hours ago
- Globe and Mail
Systemic Sclerosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Systemic Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Systemic Sclerosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Sclerosis Pipeline Outlook Key Takeaways from the Systemic Sclerosis Pipeline Report In June 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. In June 2025, GlaxoSmithKline conducted a study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life. DelveInsight's Systemic Sclerosis Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment. The leading Systemic Sclerosis Companies such as Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others. Stay ahead with the most recent pipeline outlook for Systemic Sclerosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Systemic Sclerosis Treatment Drugs Systemic Sclerosis Emerging Drugs Profile Iloprost: Eicos Sciences Iloprost is a stable analogue of PGI2 and a potent prostacyclin (IP) receptor agonist. By mimicking PGI2, it is a vasodilator and inhibitor of platelet activation and fibrosis. Iloprost stimulates generation of cAMP by binding to the IP receptor, thereby affecting phospholipase activity and cytosolic calcium levels in platelets, fibroblasts, and endothelial cells. It is a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed and investigated in Phase III stage of development for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). ECCS 50: Cytori therapeutics ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient's fat tissue and reinjecting these cells into the hands. ECCS 50 are adipose derived stem and regenerative cells (ADRCs) taken from the patient's own tissue and prepared using Cytori's cellulation system before administration. ADRCs can be used to repair and regenerate a range of damaged or diseased tissue types by differentiation of the ASRCs along the specific cell lineage, thereby replacing the damaged or missing tissue. Lenabasum (JBT-101): Corbus Pharmaceuticals Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles without evidence of immunosuppression. EHP-101: Emerald Health Pharmaceuticals EHP-101 is an oral formulation of VCE-004.8, a synthetic aminoquinone derivative of CBD with dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2) agonist activity. Both receptors are therapeutic targets for SSc. EHP-101 also modulates the hypoxia inducible factor (HIF) pathway, expanding the rationale for its development as a novel SSc drug. It is currently in phase II stage of development and is being developed by Emerald Health Pharmaceuticals. The Systemic Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Sclerosis Treatment. Systemic Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Systemic Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Sclerosis market Explore groundbreaking therapies and clinical trials in the Systemic Sclerosis Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Systemic Sclerosis Drugs Systemic Sclerosis Companies Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Molecule Type Systemic Sclerosis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Systemic Sclerosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Sclerosis Market Drivers and Barriers Scope of the Systemic Sclerosis Pipeline Report Coverage- Global Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Systemic Sclerosis Pipeline Therapies- Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others. Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Systemic Sclerosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Sclerosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Systemic Sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Iloprost: Eicos Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) EHP-101: Emerald Health Pharmaceuticals Drug profiles in the detailed report….. Early stage products (Phase I) VIB7734: Viela Bio Drug profiles in the detailed report….. Inactive Products Systemic Sclerosis Key Companies Systemic Sclerosis Key Products Systemic Sclerosis- Unmet Needs Systemic Sclerosis- Market Drivers and Barriers Systemic Sclerosis- Future Perspectives and Conclusion Systemic Sclerosis Analyst Views Systemic Sclerosis Key Companies 23. Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
8 hours ago
- CTV News
Future of Goderich and Exeter hospitals up for debate
The future of hospitals in Goderich and Exeter is up for discussion. CTV London's Scott Miller has the details. The future of hospitals in Goderich and Exeter is up for discussion. CTV London's Scott Miller has the details. There is concern amongst some Exeter residents about the future of their hospital. 'There's a discussion about building a new hospital. And if that does happen or if it ever did happen, this hospital would not be built in Exeter, and we'd like to retain our services here,' said Exeter resident Pat O'Rourke. Hospitals in Goderich and Exeter joined forces in 2022 to create the Huron Health System. Since the merger, discussion has now turned to the future of the two hospitals. The more than 100-year Alexandra Marine and General Hospital in Goderich, the largest hospital in Huron County, and the more than 70-year-old South Huron Hospital in Exeter. A special 'master planning' meeting is planned for June 11 in Bayfield. 'They are aging hospitals. And really, master planning is to develop a long-term strategy for guiding facility improvements and service delivery,' said Huron Health System CEO and President Jimmy Trieu. Jimmy Trieu Jimmy Trieu, president and CEO of the Huron Health System, in Exeter on June 10, 2025. (Scott Miller/CTV News London) O'Rourke, who spent many years as Chair of the South Huron Hospital Foundation and spent time on the combined Huron Health System Board of Directors, said he fears for the future of the South Huron Hospital. 'We've only got a population of 62,000 people here in Huron County. There's maybe seven or eight new hospitals built in the province in a year. And we think we're going to get two, never,' said O'Rourke. Officials with the Huron Health System haven't publicly said whether they are planning for one new hospital, or two new hospitals, or continued repairs to both, but tough decisions will have to be made sooner rather than later on the long term future for both hospitals. Pat O'Rourke Pat O'Rourke, former Huron Health System Board of Directors member and former chair of the South Huron Hospital Foundation on June 10, 2025. (Scott Miller/CTV News London) 'Nothing has been decided. This is the start of the master planning process and it's really to invite community members out to share their concerns and feedback to help us plan for better service delivery of health care needs in the future,' said Trieu. O'Rourke believes South Huron has gotten the short end of the stick from the 2022 merger, losing out on opportunities for a CT scanner, amongst other issues, giving him little confidence that South Huron will have an equal say about its hospital's future going forward. 'It's not a benefit to us. Prior to the merger, South Huron Hospital usually had a small surplus every year. We've been running deficits every year since this merger. Goderich used to have the deficits, now they've got the surplus,' said O'Rourke. GODERICH HOSPITAL The Alexandra Marine and General Hospital in Goderich on June 10, 2025. (Scott Miller/CTV News London) Trieu said whatever is decided, there will be many more 'master planning' sessions before any concrete steps are taken towards building one, two, or no new hospitals in Goderich, Exeter, or somewhere in between. 'You're not going to see shovels in the ground probably for the next 10 to 15 years. So, during that time we will still be here, will still be providing care for our residents in both our communities,' he said. This Wednesday's Huron Health System master planning meeting is taking place at the Bayfield Community Centre from 6:15 to 8:15 p.m.
